# Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg)

> **NCT05129137** · PHASE1 · COMPLETED · sponsor: **Unither Pharmaceuticals, France** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** nefopam hydrochloride 30mg X2
- **DRUG:** paracetamol 500 mg X2
- **DRUG:** Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2

## Key facts

- **NCT ID:** NCT05129137
- **Lead sponsor:** Unither Pharmaceuticals, France
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2021-12-27
- **Final completion:** 2021-12-27
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05129137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05129137, "Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05129137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*